C81.2 Mixed cellularity Hodgkin lymphoma

Name of the Condition

• Mixed Cellularity Hodgkin Lymphoma (ICD-10: C81.2)

Summary

Mixed cellularity Hodgkin lymphoma is a subtype of Hodgkin lymphoma characterized by a heterogeneous mix of cell types within affected lymph nodes. It is one of the classical Hodgkin lymphoma subtypes, distinguished by the presence of Reed-Sternberg cells and a variable inflammatory background. This subtype typically presents with widespread lymph node involvement and may affect other lymphoid tissues or organs.

Causes

The exact cause of mixed cellularity Hodgkin lymphoma is not fully understood, but it is associated with genetic mutations and immune system dysregulation. Epstein-Barr virus (EBV) infection is frequently linked to this subtype, suggesting a potential role in its development. Other contributing factors may include genetic predisposition and environmental exposures, though specific triggers remain under investigation.

Risk Factors

• Age: Most common in adults, with a peak incidence in the 30-50 age range.
• Gender: Slightly more prevalent in males.
• Epstein-Barr virus infection: Prior exposure increases risk.
• Immune system suppression: Conditions like HIV/AIDS or immunosuppressive therapy may elevate susceptibility.
• Family history: A first-degree relative with lymphoma may increase risk.

Symptoms

• Painless swelling of lymph nodes, often in the neck, armpits, or groin.
• Persistent fever and night sweats.
• Unexplained weight loss.
• Fatigue and weakness.
• Itching of the skin (pruritus).
• Loss of appetite.

Diagnosis

Diagnosis involves a combination of clinical evaluation and laboratory testing. A physical examination and medical history review are followed by imaging studies (e.g., CT, PET, or MRI scans) to identify affected areas. A lymph node biopsy is essential to confirm the cellular composition and rule out other conditions. Blood tests assess overall health and organ function, while bone marrow biopsies may be performed to evaluate disease spread.

Treatment Options

• Chemotherapy: The primary treatment, often using regimens like ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) to target cancer cells.
• Radiation therapy: May be used for localized disease or in combination with chemotherapy.
• Immunotherapy: Agents like brentuximab vedotin or checkpoint inhibitors may be considered for refractory cases.
• Stem cell transplantation: Reserved for relapsed or high-risk disease.

Prognosis and Follow-Up

Prognosis depends on factors like disease stage, age, and response to treatment. Most patients achieve remission with standard therapy, though relapses can occur. Long-term follow-up is necessary to monitor for recurrence, secondary cancers, or treatment-related complications. Regular imaging and blood tests are typically part of surveillance.

Complications

• Recurrence of lymphoma.
• Secondary malignancies, such as leukemia or solid tumors, due to treatment.
• Infection risk from immunosuppression.
• Cardiovascular or pulmonary issues from chemotherapy or radiation.
• Fertility problems from treatment.

Lifestyle & Prevention

• Maintain a balanced diet and regular exercise to support overall health.
• Avoid tobacco and limit alcohol consumption.
• Practice good hygiene to reduce infection risk.
• Stay up-to-date with vaccinations, as recommended by a healthcare provider.
• Manage stress through relaxation techniques or support groups.

When to Seek Professional Help

Seek medical attention if you experience persistent lymph node swelling, unexplained weight loss, fever, or night sweats. Prompt evaluation is important for early diagnosis and treatment. Contact a healthcare provider if symptoms worsen or new symptoms develop during or after treatment.

Tips for Medical Coders

Document the specific subtype (mixed cellularity) and any relevant details about disease extent or treatment. Ensure the code C81.2 is used for mixed cellularity Hodgkin lymphoma without additional site modifiers, as the code itself represents the subtype. Verify that clinical documentation supports the diagnosis and aligns with the ICD-10-CM coding guidelines for lymphomas.